Pharmacy Pearls: Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Comparison

Pharmacy Pearls: Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Comparison

May 25th, 2022 | Pharmacy PearlsPain Management

In this edition of Pharmacy Pearls, we compare the gastrointestinal (GI) and cardiovascular (CV) risks of the most common non-selective and selective non-steroidal anti-inflammatory drugs (NSAIDs). You will also find strategies to mitigate NSAID-related GI risks for primary and secondary prevention.

As a reminder, one of AHP’s 2022 pharmacy opportunities is to avoid the use of brand-name NSAID products when possible (e.g., Cambia®, Celebrex®, Flector® patch, Arthrotec® ) and to switch patients who are prescribed combination naproxen/esomeprazole (~$900 per prescription) or diclofenac/misoprostol (~$130 per prescription) to individual agents. The least expensive NSAID therapy options include meloxicam, ibuprofen, naproxen, indomethacin (IR/ER), diclofenac sodium DR, sulindac, ketorolac (IR only), and celecoxib (~$2-25 per prescription).

As always, we welcome any questions or feedback you may have. Just email the Pharmacy Team.

Loader Loading...
EAD Logo Taking too long?

Reload Reload document
| Open Open in new tab

Download PDF [254.12 KB]